-
Mashup Score: 1Nonsteroidal anti-inflammatory drugs as a targeted therapy for bone marrow failure in Ghosal hematodiaphyseal dysplasia - 1 year(s) ago
Key Points. NSAIDs can normalize hematologic parameters and serum inflammatory markers in patients with Ghosal hematodiaphyseal dysplasia syndrome.Prostaglandin
Source: American Society of HematologyCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1Blocking COX unlocks response in GHDD - 1 year(s) ago
In this issue of Blood, Brown et al show that novel therapy with intermediate- to high-dose nonsteroidal antiinflammatory drugs (NSAIDs) overcomes augmented inf
Source: American Society of HematologyCategories: Hem/Oncs, Latest HeadlinesTweet-
So stoked to see a companion article with a legendary title from former @UTSWInternalMed @UTSWIMchief co-resident (now full fledged hematologist @bcmhouston ) @SSukumarMD ! @dhjutsw1 @DinoKazi https://t.co/UFzv3HmVt6
-
-
Mashup Score: 0My Journey Through the Hematology / Oncology Fellowship Match - 1 year(s) ago
Dr. Michael LaPelusa shares his recent start-to-finish experience going through the Fellowship Match, with tips for preparing your application, interviewing, and telling your unique professional story.
Source: ASCO ConnectionCategories: Hem/Oncs, Latest HeadlinesTweet-
“My Journey Through the Hematology / Oncology Fellowship Match” nice article by @MichaelLaPelusa in @ASCO connection https://t.co/bHjpcqzxto
-
-
Mashup Score: 1Philly residents advised to drink bottled water Sunday afternoon following chemical spill, officials say - 1 year(s) ago
While no contaminants have been found in the city’s water system following Friday’s spill in Bucks County, “we cannot be 100% certain” there will not be chemicals Sunday afternoon, an official said.
Source: https://www.inquirer.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Philly..... https://t.co/na3NFUBMsW
-
-
Mashup Score: 3Peripheral Neuropathy - 1 year(s) ago
This patient page describes the risks, symptoms, complications, and recommended treatment options for chemotherapy-induced peripheral neuropathy.
Source: jamanetwork.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Sharing this @JAMAOnc #PatientPage on Chemotherapy Induced Peripheral Neuropathy with @guptaarjun90 @ramsedhom since @ravi_b_parikh brought it up at noon conf today https://t.co/BBHrQBXiD1
-
-
Mashup Score: 1Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma - 1 year(s) ago
Survival after sorafenib initiation in newly diagnosed Medicare beneficiaries with hepatocellular carcinoma (HCC) is exceptionally short, suggesting that trial
Source: OUP AcademicCategories: Hem/Oncs, Latest HeadlinesTweet-
@NiuSanford @flatironhealth @tjroycemd Thanks @NiuSanford! Agree the discrepancy is striking, similar to what @DusetzinaS found with sorafenib in HCC https://t.co/GWW3gYAFqK
-
-
Mashup Score: 1Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study - 1 year(s) ago
IMbrave150 has established the superiority of atezolizumab plus bevacizumab over sorafenib in patients with unresectable hepatocellular carcinoma (HCC).
Source: European Journal of CancerCategories: Hem/Oncs, Latest HeadlinesTweet-
@NiuSanford @flatironhealth @tjroycemd @DusetzinaS Although @FulgenziClaudia found mOS of 15 months in their prospective real world analysis of atezo bev in HCC https://t.co/L2wo2w0OL0 Will need to be followed closely in the coming years!
-
-
Mashup Score: 0
In hepatocellular carcinoma driven by non-alcoholic steatohepatitis, aberrant T cell activation and impaired immune surveillance seem to make hepatocellular carcinoma less responsive to anti-PD1 or anti-PDL1 immunotherapy.
Source: NatureCategories: Hem/Oncs, Latest HeadlinesTweet-
This question was inspired by the study by Pfister & co @Nature 2021 who identified a signal for worse outcomes in non-viral HCC treated with IO https://t.co/utdngx5p0q
-
-
Mashup Score: 0Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study - 1 year(s) ago
IMbrave150 has established the superiority of atezolizumab plus bevacizumab over sorafenib in patients with unresectable hepatocellular carcinoma (HCC).
Source: European Journal of CancerCategories: Hem/Oncs, Latest HeadlinesTweet-
Since initiating this study, several other similar papers have been published on the topic, perhaps topped by really elegant work by @FulgenziClaudia and colleagues with similar conclusions published in EJC here: https://t.co/L2wo2w0OL0
-
-
Mashup Score: 7
Purpose Hepatocellular carcinoma (HCC) is a common and deadly form of liver cancer. Combination atezolizumab and bevacizumab has improved the outcomes for patients with advanced disease. We sought to determine the impact of etiology on outcomes of patients treated with atezolizumab and bevacizumab. Methods This study used a real-world database. The primary outcome was overall survival (OS) by…
Source: SpringerLinkCategories: Hem/Oncs, Latest HeadlinesTweet-
Again grateful outstanding guidance from mentors at @PennCancer. Read our full work here: https://t.co/lHk7oerRKD Interested in any comments/feedback
-
Out now (eh a few days ago) in JCRCO – part of my thesis @UPennDBEI @PennCancer @PC3Innovation @Ron_cology Karasic, Gimotty, and Yang “Outcomes of hepatocellular carcinoma by etiology with first‑line atezolizumab and bevacizumab: a real‑world analysis” 🧵 https://t.co/lHk7oerRKD
-
Out now in @BloodJournal - our paper on NSAIDS in Ghosal syndrome (@BabushokLab @dr_barrett) https://t.co/c7LR2yiSnr